- Tiger's Tale to Put Other Athletes' Pitch Deals in Rough
- Deficits Must Be Curbed or Economy Doomed: Study
- Obama To Bankers: Help Economy, Support Regulations
- SAC Capital Has a Reverse Midas Touch With Spinoffs
- ExxonMobil to Buy XTO Energy in $31 Billion Deal
- Cramer: Does XTO’s CEO Deserve $171 Million?
- Hot Tech Trades For 2010
- Dubai's Bailout: A Break, but Not Much More
- U.S. Could See $13-14 Billion Profit on Citi—Official
- Ford Eyes Big 2010 as Europe Sales Surge
- Cavaliers Close To Selling Stake To Chinese Businessman
- Google Phone No Threat to Apple: Tech Analysts
- Viva Las Vegas? Keep Watching CityCenter
- Dec. 14: Unusual Volume Leaders
- Where Would You Invest $100 Billion?
- Google Preps to Hit Apple Where it Hurts
- Beware of Emerging Market Bubble: Strategist
- S&P 1200-1250 'Very Possible' in 2010: Chief Investor
MOST SHARED
- Viva Las Vegas? Keep Watching CityCenter
- Kneale: Obama, the Banks, and the 'F' Word
- Deficits Must Be Curbed or It's Disaster For Economy: Study
- Obama To Bankers: Help Economy, Support Regulations
- Worst of Bank Failures Isn't Over Yet: FDIC's Bair
- Hot Tech Trades For 2010
- After Christmas Shopping May Fall: Survey
- Cavaliers Close To Selling Stake To Chinese Businessman
- Cramer: 10 Stocks to Buy Your Kids in 2010
FEATURED QUIZZES
Novo Nordisk Diabetes Drug May Aid Weight Loss
Text Size 
A new study shows that a diabetes treatment awaiting FDA approval may also work as a weight loss drug.
 |
AP |
Obese patients who took various doses of the one-a-day injectable Victoza from Novo Nordisk [NVO
Loading...
()
] lost between 10 and 14 pounds.
That compares to nine pounds shed by clinical trial participants who took the prescription diet pill Xenical from Roche [RHHBY
Loading...
()
], which is also sold without a prescription by GlaxoSmithKline [GSK
Loading...
()
] in lower doses under the brand name Alli. The results are in the new issue of the British medical journal "The Lancet."
In addition, three out of four patients who got Victoza lost at least 5 percent of their body weight. And it cut the prevalence of so-called prediabetes by 84-96 percent.
The FDA is deciding whether to approve Victoza as a diabetes treatment. It would compete with a similar drug Byetta from Eli Lilly [LLY
Loading...
()
] and Amylin Pharmaceuticals [AMLN
Loading...
()
].
Researchers say longer-term studies need to be done on Victoza in the obese population, but this study shows its potential as an "important" treatment for obese prediabetics.
A Novo spokesperson did not provide a comment on the study.
Print
Email
- As the radio plays Christmas music seemingly nonstop, which songs are consumers actually buying?
- Some said it would never happen, but here comes Aria. Keep watching CityCenter, says Jane Wells.
- President Obama still doesn’t get it, says Dennis Kneale. Name-calling the big banks won't help mend the economy.
- From the bar-room bookie deals to the simple Super Bowl office pool, millions of people are in on the action.
- This year, consumers are buying at a faster pace than they bought previous generations of movie players.
- New surveys show that more Americans are making New Year resolutions to improve their finances.
Data is a real-time snapshot *Data is delayed at least 15 minutes